AHA 2026
Powerful Medical will be in Chicago for Scientific Sessions. Whether or not you find us on the show floor, reach out to arrange a meeting — we'd love to share our latest clinical evidence and discuss AI-driven cardiac diagnostics.
Chicago, Illinois, USA
November 6–9, 2026
Scientific Sessions is the American Heart Association's largest cardiovascular conference of the year, bringing together the brightest minds in cardiovascular medicine and science for four days of groundbreaking research, expert-led education and networking. Around 10,000 clinicians, researchers and industry leaders attend.
The 2026 programme introduces new formats and tracks, including Core Cardiology for clinicians focused on evidence-based care, alongside immersive experiences in AI, simulation and guideline-driven care across 21 education communities. The Health Innovation Pavilion in the Science & Technology Hall is dedicated to AI and digital health, where clinicians, founders, investors and health systems meet.
Exhibits are open 7–9 November.
- Venue: McCormick Place Convention Center, Chicago, Illinois, USA
- Organiser: American Heart Association (AHA)
- Website: professional.heart.org
Share this article
About PMcardio
PMcardio features FDA-authorized and CE-marked AI ECG models that interpret any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.